Product info

Smart Health Care offers services concerning early diagnosis (step 1) and personalized treatment (step 3), all as a decision support system to the physicians. Read more on each step of the scheme below.

In recent years, there has been a tremendous advancement in large-scale data generation and development of new therapeutic methods. Interpreting this huge amount of data in a meaningful manner is a hurdle since no one physician can know everything. Consequently, a gap has appeared between the in-hand knowledge and the in-use methods. Besides, heterogeneous nature of cancer makes it very difficult to apply a generic treatment and diagnosis method. SHC develops a deep learning algorithm which facilitates recognition and categorization of cancer specific patterns. The outcome would be a report as an extra decision support signal to the physician which determines in minutes what could take months of try and error. The immediate consequence could be early cancer diagnosis through regular medical assessments.  
The conventional cancer diagnosis is initially based on a combination of a number of indicators. The indicators could consist of a range of symptoms such as drastic weight loss, weakened immune system, etc. The more detailed assessments include mammography, colonoscopy, gastroscopy, tumor biopsy etc..
Mapping individual subjects into the emergent patterns from SHC algorithm would help both early diagnosis and effective targeted treatment by knowing how previous patients responded to treatment. This together with personal data of the patient leads to synthesize modern capacities for providing personalized care unique to every individual.     
Based on type and stage of the cancer, different treatment methods are in use to remove the tumor or decrease its growth rate. Surgical eradication of tumors is the most common type of cancer treatment. Hormone therapy and radiotherapy were developed early 20th century and followed by chemotherapy and immunotherapy. Novel targeted therapy methods emerged late 20th and are growing in line with advancements in technology and increased understanding of biological mechanisms underlying tumorigenesis.
Waiting phase
A period of time needs to be passed before the effect of any treatment could be assessed. The conventional treatment processes are not designed to be unique, and therefore more efficient, for every patient. Targeted treatments can shorten the waiting phase dramatically.
Non-targeted treatments leave a vast space for try and error. Thus there is a need for more frequent reassessments which translates as a long waiting phase before the most efficient treatment is found and applied. Personalized treatments suggested based on SHC solutions can reduce the number of reassessment rounds and save time.